TLR9 and osteosarcoma: We provide evidence that intratumoral administration of SD101, a type C CpG oligonucleotide triggering TLR9, into mouse osteosarcoma models induces a massive reprogramming of the tumor microenvironment (TME), sufficient to halt the growth of treated and also of contralateral untreated lesions (graphical abstract).